Incannex Healthcare (IXHL) Return on Capital Employed (2024 - 2026)
Incannex Healthcare (IXHL) posted quarterly Return on Capital Employed of 33.5% for Q1 2026, up 38036.0% year-on-year from N/an in Q1 2025, and up 4.14% on a QoQ basis from 34.95% in Q4 2025.
Incannex Healthcare (IXHL) Return on Capital Employed (2024 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Return on Capital Employed for 3 consecutive years, with 33.5% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed rose 38036.0% year-over-year to 33.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 33.5% (up 38036.0% YoY) and the FY2025 annual result came in at 202.24%, up 81.0% from the prior year.
- Return on Capital Employed grew to 33.5% in Q1 2026 per IXHL's latest filing, from 34.95% in the prior quarter.
- Over the last five years, Return on Capital Employed for IXHL reached as high as 33.5% in Q1 2026 and fell as low as 429.17% in Q3 2024.
- A 3-year average of 216.04% and a median of 209.82% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 26933 bps — and 2026, when it soared 38036 bps.
- Year by year, Return on Capital Employed stood at 367.29% in 2024, then soared by 90 bps to 34.95% in 2025, then climbed by 4 bps to 33.5% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 33.5%, 34.95%, and 50.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | -33.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.50% |
| Dec 31, 2025 | -34.95% |
| Sep 30, 2025 | -50.75% |
| Jun 30, 2025 | -209.82% |
| Mar 31, 2025 | -413.86% |
| Dec 31, 2024 | -367.29% |
| Sep 30, 2024 | -429.17% |
| Jun 30, 2024 | -260.52% |
| Mar 31, 2024 | -144.53% |